Pharmaceuticals Europe

Europe Long-Acting HIV Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $390.8 Mn Placeholder estimate
Estimate 2025 $463.5 Mn 16.1% of the global market
Projected 2034 $2.15 Bn 364.3% Adds $1.69 Bn over 9 forecast years
CAGR 2025–2034 18.6% Faster than 87% of 180 Pharmaceuticals markets here
Key players 4
  • Europe is 16.09% of the global market.
  • Among regions, the largest is North America at $1.48 Bn.
  • Fastest growing: APAC at 21.6% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.69 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Long-Acting HIV Treatment Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $390.8 Mn — —
2025 (base) $463.5 Mn +$72.7 Mn —
2026 (forecast) $549.7 Mn +$86.2 Mn +18.6%
2027 (forecast) $651.9 Mn +$102.2 Mn +40.7%
2028 (forecast) $773.2 Mn +$121.3 Mn +66.8%
2029 (forecast) $917.0 Mn +$143.8 Mn +97.9%
2030 (forecast) $1.09 Bn +$170.6 Mn +134.7%
2031 (forecast) $1.29 Bn +$202.3 Mn +178.3%
2032 (forecast) $1.53 Bn +$239.9 Mn +230.1%
2033 (forecast) $1.81 Bn +$284.5 Mn +291.5%
2034 (forecast) $2.15 Bn +$337.5 Mn +364.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Long-Acting HIV Treatment Market Analysis at a glance
Market size, 2025$463.5 Mn placeholder estimate
Forecast, 2034$2.15 Bn placeholder estimate
Growth (CAGR), 2025–203418.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsUse, drug and end user (see all)
Key playersViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials16 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Long-Acting HIV Treatment Market Analysis Executive Summary

Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.

Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).

Bar chart: Europe Long-Acting HIV Treatment market size, 2024–2034, placeholder estimates. $390.8 Mn in 2024, $463.5 Mn in 2025 and $2.15 Bn in 2034, 18.6% CAGR.
Europe Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Long-Acting HIV Treatment Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.

Competitive Landscape for Long-Acting HIV Treatment Market in Europe

The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in Europe

Long-Acting HIV Treatment in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], CBG-MEB (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15] ClinicalTrials.gov lists 16 studies on Long-Acting HIV Treatment that are recruiting, active or about to start in Europe.⁠[16]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.

[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.

[10] Swissmedic. Checked 19 Nov 2026.

[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.

[12] Danish Medicines Agency. Checked 19 Nov 2026.

[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.

[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.

[15] European Commission, health technology assessment. Checked 14 Nov 2026.

[16] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.

Clinical trials

16 active trials in UK, Germany, France, Italy, Spain, Netherlands, Belgium, Switzerland, Sweden, Denmark, Poland, Turkey and Russia

Recruiting, about to start, or running now. Counted across the 13 countries we report on in Europe.

Top trial sponsors (worldwide)

  1. ViiV Healthcare 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Gilead Sciences, Inc. 6 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

New HIV infections, people (WHO)
CountryValueYear
Belgium5002025
Denmark1002024
France3,4002024
Germany2,3002024
Italy3,7002025
Netherlands5002024
Spain3,1002025
Sweden2002024
Switzerland5002025
UK2,1002024
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Long-Acting HIV Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Long-Acting HIV Treatment market in Europe?
Placeholder estimate: about $463.5 Mn in 2025, rising to about $2.15 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in Europe growing?
Placeholder estimate: about 18.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Who regulates Long-Acting HIV Treatment in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Long-Acting HIV Treatment are running in Europe?
16 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Long-Acting HIV Treatment?
PubMed lists 17 papers on Long-Acting HIV Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on hiv and infectious diseases

See the topic